Discovery of 3-(2,6-Dichloro-3,5-dimethoxy-phenyl)-1-{6-[4-(4-ethyl-piperazin-1-yl)-phenylamino]-pyrimidin-4-yl}-1-methyl-urea (NVP-BGJ398), A Potent and Selective Inhibitor of the Fibroblast Growth Factor Receptor Family of Receptor Tyrosine Kinase

被引：396

作者：

Guagnano, Vito ^{[1
]}

Furet, Pascal ^{[1
]}

Spanka, Carsten ^{[1
]}

Bordas, Vincent ^{[1
]}

Le Douget, Mickael ^{[1
]}

Stamm, Christelle ^{[1
]}

Brueggen, Josef ^{[1
]}

Jensen, Michael R. ^{[1
]}

Schnell, Christian ^{[1
]}

Schmid, Herbert ^{[1
]}

Wartmann, Markus ^{[1
]}

Berghausen, Joerg ^{[1
]}

Drueckes, Peter ^{[1
]}

Zimmerlin, Alfred ^{[1
]}

Bussiere, Dirksen ^{[1
]}

Murray, Jeremy ^{[1
]}

Porta, Diana Graus ^{[1
]}

机构：

[1] Novartis Inst BioMed Res, CH-4002 Basel, Switzerland

来源：

JOURNAL OF MEDICINAL CHEMISTRY | 2011年 / 54卷 / 20期

关键词：

HUMAN BREAST; MULTIPLE-MYELOMA; MYELOPROLIFERATIVE SYNDROME; ONCOGENE AMPLIFICATION; ACTIVATING MUTATIONS; GENE AMPLIFICATION; FGF FAMILY; INT-2; GENE; EXPRESSION; CANCER;

D O I：

10.1021/jm2006222

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

A novel series of N-aryl-N'-pyrimidin-4-yl ureas has been optimized to afford potent and selective inhibitors of the fibroblast growth factor receptor tyrosine kinases 1, 2, and 3 by rationally designing the substitution pattern of the aryl ring. On the basis of its in vitro profile, compound 1h (NVP-BGJ398) was selected for in vivo evaluation and showed significant antitumor activity in RT112 bladder cancer xenografts models overexpressing wild-type FGFR3. These results support the potential therapeutic use of 1h as a new anticancer agent.

引用

页码：7066 / 7083

页数：18

共 61 条

[1]

ADNANE J, 1991, ONCOGENE, V6, P659

[2] THE CCP4 SUITE - PROGRAMS FOR PROTEIN CRYSTALLOGRAPHY [J].

BAILEY, S .

ACTA CRYSTALLOGRAPHICA SECTION D-BIOLOGICAL CRYSTALLOGRAPHY, 1994, 50 :760-763

[3]

BAIROCH A, 1994, NUCLEIC ACIDS RES, V22, P3578

[4] The FGF family: biology, pathophysiology and therapy [J].

Beenken, Andrew ;

Mohammadi, Moosa .

NATURE REVIEWS DRUG DISCOVERY, 2009, 8 (03) :235-253

[5] 8pII myeloproliferative syndrome with a novel t(7;8) translocation leading to fusion of the FGFRI and TIFI genes [J].

Belloni, E ;

Trubia, M ;

Gasparini, P ;

Micucci, C ;

Tapinassi, C ;

Confalonieri, S ;

Nuciforo, P ;

Martino, B ;

Lo-Coco, F ;

Pelicci, PG ;

Di Fiore, PP .

GENES CHROMOSOMES & CANCER, 2005, 42 (03) :320-325

[6] ONCOGENE AMPLIFICATION AND PROGNOSIS IN BREAST-CANCER - RELATIONSHIP WITH SYSTEMIC TREATMENT [J].

BERNS, EMJJ ;

FOEKENS, JA ;

VANSTAVEREN, IL ;

VANPUTTEN, WLJ ;

DEKONING, HYWCM ;

PORTENGEN, H ;

KLIJN, JGM .

GENE, 1995, 159 (01) :11-18

[7] Discovery and preclinical studies of (R)-1-(4-(4-fluoro-2-methyl-1H-indol-5-yloxy)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy)propan-2-ol (BMS-540215), an in vivo active potent VEGFR-2 inhibitor [J].

Bhide, RS ;

Cai, ZW ;

Zhang, YZ ;

Qian, LG ;

Wei, D ;

Barbosa, S ;

Lombardo, LJ ;

Borzilleri, RM ;

Zheng, XP ;

Wu, LI ;

Barrish, JC ;

Kim, SH ;

Leavitt, K ;

Mathur, A ;

Leith, L ;

Chao, S ;

Wautlet, B ;

Mortillo, S ;

Jeyaseelan, R ;

Kukral, D ;

Hunt, JT ;

Kamath, A ;

Fura, A ;

Vyas, V ;

Marathe, P ;

D'Arienzo, C ;

Derbin, G ;

Fargnoli, J .

JOURNAL OF MEDICINAL CHEMISTRY, 2006, 49 (07) :2143-2146

[8] Frequent FGFR3 mutations in papillary non-invasive bladder (pTa) tumors [J].

Billerey, C ;

Chopin, D ;

Aubriot-Lorton, MH ;

Ricol, D ;

de Medina, SGD ;

Van Rhijn, B ;

Bralet, MP ;

Lefrere-Belda, MA ;

Lahaye, JB ;

Abbou, CC ;

Bonaventure, J ;

Zafrani, ES ;

van der Kwast, T ;

Thiery, JP ;

Radvanyi, F .

AMERICAN JOURNAL OF PATHOLOGY, 2001, 158 (06) :1955-1959

[9]

Bricogne G., 2010, BUSTER 2 9

[10] Frequent activating mutations of FGFR3 in human bladder and cervix carcinomas [J].

Cappellen, D ;

De Oliveira, C ;

Ricol, D ;

de Medina, SGD ;

Bourdin, J ;

Sastre-Garau, X ;

Chopin, D ;

Thiery, JP ;

Radvanyi, F .

NATURE GENETICS, 1999, 23 (01) :18-20

← 1 2 3 4 5 6 7 →